fda glp-1 safety warning september 2025 How Crackdowns Are Affecting Use In Novo Hit With FDA Warning

Abstract Recent advancements in obesity pharmacotherapy have seen the approval of novel agents, like glucagon-like peptide-1 receptor agonist and dual agonists, offering unprecedented efficacy for obesity management

Another highly effective strategy is food sequencing

However, developing an effective, safe, and tolerable oral small-molecule GLP-1 has proven incredibly challenging

Semaglutide has shown a reduction in liver fat content, but not a statistically significant improvement in liver fibrosis or remission of MASH 6

Will new obesity agents further limit or prevent lean muscle mass reduction

Anthem commercial plans in Michigan that may include GLP-1 or obesity medication coverage include certain PPO and HMO plans where the employer has elected to include obesity drug benefits